Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Kushal Naha

Hematology | Hematology Oncology | Oncology
Parkview Health
Parkview Health System Inc
11050 Parkview Circle Dr, 
Fort Wayne, IN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Advanced in WT1-Related Wilms Tumor Syndromes
Parkview Health
Parkview Health System Inc
11050 Parkview Circle Dr, 
Fort Wayne, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kushal Naha is a Hematologist and a Hematologist Oncology provider in Fort Wayne, Indiana. Dr. Naha is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, Colonoscopy, and Endoscopy. Dr. Naha is currently accepting new patients.

His clinical research consists of co-authoring 59 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Hematology Oncology
Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Parkview Regional Medical Center
University Of Missouri Health Care
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

PARKVIEW HEALTH SYSTEM INC
11050 Parkview Circle Dr, Fort Wayne, IN 46845
Call: 260-266-5260
Other Locations
PARKVIEW HEALTH SYSTEM INC
817 Trail Ridge Rd, Albion, IN 46701
Call: 260-373-9590

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


4 Clinical Trials

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase II Randomized Trial of Immunotherapy Versus Immunotherapy and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (IMMORTAL)
Phase II Randomized Trial of Immunotherapy Versus Immunotherapy and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (IMMORTAL)
Enrollment Status: Terminated
Publish Date: August 17, 2025
Intervention Type: Procedure, Other, Biological, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 2
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
CASPAR - a Phase III Trial of Enzalutamide and Rucaparib As a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Other, Drug
Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix
Study Phase: Phase 3
View 3 Less Clinical Trials

58 Total Publications

Impact of Tumor Location on Predicting Early-Stage Breast Cancer Patient Survivability Using Explainable Machine Learning Models.
Impact of Tumor Location on Predicting Early-Stage Breast Cancer Patient Survivability Using Explainable Machine Learning Models.
Journal: JCO clinical cancer informatics
Published: March 31, 2025
View All 58 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Zhentao Zhang
Hematology Oncology | Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Zhentao Zhang
Hematology Oncology | Oncology | Hematology

Parkview Health System Inc

11104 Parkview Circle Dr, 
Fort Wayne, IN 
 (0.1 miles away)
206-266-5400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Zhentao Zhang is a Hematologist Oncology specialist and an Oncologist in Fort Wayne, Indiana. Dr. Zhang is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Adult Soft Tissue Sarcoma, and Non-Muscle Invasive Bladder Cancer. Dr. Zhang is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Farrukh M. Adhami
Oncology | Hematology Oncology | Hematology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Farrukh M. Adhami
Oncology | Hematology Oncology | Hematology

American Oncology Partners PA

7910 W Jefferson Blvd, Suite 108, 
Fort Wayne, IN 
 (12.9 miles away)
260-436-0800
Languages Spoken:
English, French, German
See accepted insurances
Accepting New Patients

Farrukh Adhami is an Oncologist and a Hematologist Oncology provider in Fort Wayne, Indiana. Dr. Adhami is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Childhood Iron Deficiency Anemia, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Thrombocytopenia, and Iron Deficiency Anemia. Dr. Adhami is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Sunil Babu
Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Sunil Babu
Hematology | Oncology

American Oncology Partners PA

2514 E Dupont Rd, Suite 100, 
Fort Wayne, IN 
 (0.9 miles away)
260-484-8830
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sunil Babu is a Hematologist and an Oncologist in Fort Wayne, Indiana. Dr. Babu is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Thrombocytopenia, Atypical Hemolytic Uremic Syndrome (aHUS), Hemolytic-Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, and Bone Marrow Aspiration.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Naha's expertise for a condition
ConditionClose
      • Advanced
      • Chromophobe Renal Cell Carcinoma
        Dr. Naha is
        Advanced
        . Learn about Chromophobe Renal Cell Carcinoma.
        See more Chromophobe Renal Cell Carcinoma experts
      • Clear Cell Sarcoma
        Dr. Naha is
        Advanced
        . Learn about Clear Cell Sarcoma.
        See more Clear Cell Sarcoma experts
      • Familial Wilms Tumor 2
        Dr. Naha is
        Advanced
        . Learn about Familial Wilms Tumor 2.
        See more Familial Wilms Tumor 2 experts
      • Renal Cell Carcinoma (RCC)
        Dr. Naha is
        Advanced
        . Learn about Renal Cell Carcinoma (RCC).
        See more Renal Cell Carcinoma (RCC) experts
      • Wilms Tumor
        Dr. Naha is
        Advanced
        . Learn about Wilms Tumor.
        See more Wilms Tumor experts
      • WT1-Related Wilms Tumor Syndromes
        Dr. Naha is
        Advanced
        . Learn about WT1-Related Wilms Tumor Syndromes.
        See more WT1-Related Wilms Tumor Syndromes experts
      • Experienced
      • Acute Mountain Sickness
        Dr. Naha is
        Experienced
        . Learn about Acute Mountain Sickness.
        See more Acute Mountain Sickness experts
      • Adult Immune Thrombocytopenia
        Dr. Naha is
        Experienced
        . Learn about Adult Immune Thrombocytopenia.
        See more Adult Immune Thrombocytopenia experts
      • Adult Soft Tissue Sarcoma
        Dr. Naha is
        Experienced
        . Learn about Adult Soft Tissue Sarcoma.
        See more Adult Soft Tissue Sarcoma experts
      • Anemia
        Dr. Naha is
        Experienced
        . Learn about Anemia.
        See more Anemia experts
      • Bladder Cancer
        Dr. Naha is
        Experienced
        . Learn about Bladder Cancer.
        See more Bladder Cancer experts
      • Childhood Iron Deficiency Anemia
        Dr. Naha is
        Experienced
        . Learn about Childhood Iron Deficiency Anemia.
        See more Childhood Iron Deficiency Anemia experts
      View All 32 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2025 All Rights Reserved